<DOC>
	<DOCNO>NCT01514864</DOCNO>
	<brief_summary>The purpose study establish whether patient malignancy harbor discoidin domain receptor 2 mutation inactivate B-RAF mutation respond dasatinib .</brief_summary>
	<brief_title>Trial Dasatinib Patients With Advanced Cancers Harboring DDR2 Mutation Inactivating B-RAF Mutation</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Diagnosis advance malignancy , nonsmallcell lung cancer ( NSCLC ) stage 1 accrual Nonsynonymous mutation BRAF DDR2 , define follow : NSCLC inactivate BRAF mutation NSCLC discoidin domain receptor 2 ( DDR2 ) mutation Malignancy histology DDR2 mutation inactivate BRAF mutation , NSCLC BRAF mutation functionally characterize At least 1 target lesion per Response Evaluation Criteria Solid Tumors , vol 1.1 , baseline stag evaluation Disease progression ≥ 1 prior treatment regimen Pleural pericardial effusion , Grade &gt; 1 QTcF &gt; 470 msec ( Grade ≥2 ) diagnose congenital long QT syndrome Absolute granulocyte count &lt; 1500/mm^3 Hemoglobin level &lt; 10 g/dL Platelet count &lt; 75,000/mm^3 Serum calcium level &lt; institutional low limit normal Hypokalemia , hypophosphatemia , hypomagnesemia , Grade &gt; 1 , despite supplementation Creatinine &gt; 3*institutional upper limit normal ( ULN ) Total bilirubin level &gt; 1.5*ULN Alanine transaminase level &gt; 3*ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>